Labcorp Execs to Discuss Strategy at Morgan Stanley Healthcare Conference
Event summary
- Labcorp execs to participate in fireside chat at Morgan Stanley Global Healthcare Conference on Sept. 15, 2026.
- Live audio webcast available via Labcorp Investor Relations website.
- Archived replay accessible for 180 days post-event.
- Labcorp supports 85% of FDA-approved new drugs and therapeutic products in 2025.
- Company performed over 750 million tests globally in 2025.
The big picture
Labcorp's participation in the Morgan Stanley conference comes as the diagnostics industry faces pressure to innovate and scale. With a significant footprint in both diagnostics and drug development, Labcorp's strategic updates will be closely watched by investors and competitors alike. The company's role in supporting 85% of FDA-approved new drugs underscores its critical position in the healthcare ecosystem.
What we're watching
- Strategic Positioning
- How Labcorp will position itself amid increasing competition in the diagnostics sector.
- Regulatory Influence
- Whether Labcorp's dominance in FDA-approved drug support will face regulatory scrutiny.
- Operational Scale
- The pace at which Labcorp can sustain its global test volume growth.
Related topics